Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Nephrology Institute, Schneider Children's Medical Center, Petach Tikva, Israel.
Pediatr Nephrol. 2023 Oct;38(10):3445-3454. doi: 10.1007/s00467-023-05905-1. Epub 2023 Apr 20.
Kidney trans plantation is associated with secondary complications, including the risk of developing posttransplant cytopenias. This study aimed to evaluate the characteristics, identify predictors, and assess the management and consequences of cytopenias in the pediatric kidney transplant population.
This is a single-center retrospective analysis of 89 pediatric kidney transplant recipients. Possible factors preceding cytopenias were compared with the goal of recognizing predictors for posttransplant cytopenias. Posttransplant neutropenias were analyzed for the total study period and separately for the period beyond 6 months posttransplant (late neutropenias), to rule out confounding influences of induction and initial intensive therapy.
Sixty patients (67%) developed at least one episode of posttransplant cytopenia. All episodes of posttransplant thrombocytopenias were mild or moderate. Posttransplant infections and graft rejection were found to be significant predictors for thrombocytopenia (HR 6.06, 95% CI 1.6-22.9, and HR 5.82, 95% CI 1.27-26.6, respectively). A total of 30% of posttransplant neutropenias were severe (ANC ≤ 500). Pretransplant dialysis and posttransplant infections were significant predictors for late neutropenias (HR 11.2, 95% CI 1.45-86.4, and HR 3.32, 95% CI 1.46-7.57, respectively). Graft rejection occurred in 10% of patients with cytopenia, all following neutropenia, within 3 months from cytopenia appearance. In all such cases, mycophenolate mofetil dosing had been held or reduced prior to rejection.
Posttransplant infections are substantial contributors to developing posttransplant cytopenias. Preemptive transplantation appears to reduce risk of late neutropenia, the accompanying reduction in immunosuppressive therapy, and the ensuing risk of graft rejection. An alternative response to neutropenia, possibly using granulocyte colony stimulating factor, may diminish graft rejection. A higher resolution version of the Graphical abstract is available as Supplementary information.
肾移植会引起继发性并发症,包括发生移植后血细胞减少症的风险。本研究旨在评估儿科肾移植人群中血细胞减少症的特征、确定预测因素,并评估其管理和后果。
这是一项对 89 例儿科肾移植受者进行的单中心回顾性分析。对发生血细胞减少症之前的可能因素进行了比较,以期识别移植后血细胞减少症的预测因素。对整个研究期间和移植后 6 个月以上(迟发性中性粒细胞减少症)的移植后中性粒细胞减少症进行了分析,以排除诱导和初始强化治疗的混杂影响。
60 例(67%)患者至少发生了一次移植后血细胞减少症。所有移植后血小板减少症均为轻度或中度。移植后感染和移植物排斥被认为是血小板减少症的显著预测因素(HR 6.06,95%CI 1.6-22.9 和 HR 5.82,95%CI 1.27-26.6)。移植后中性粒细胞减少症中,30%为重度(ANC≤500)。移植前透析和移植后感染是迟发性中性粒细胞减少症的显著预测因素(HR 11.2,95%CI 1.45-86.4 和 HR 3.32,95%CI 1.46-7.57)。10%的血细胞减少症患者发生了移植物排斥反应,均在血细胞减少出现后 3 个月内,且均在中性粒细胞减少之后发生。在所有这些病例中,排斥反应发生前,霉酚酸酯剂量已被暂停或减少。
移植后感染是导致移植后血细胞减少症的重要因素。预防性移植似乎降低了迟发性中性粒细胞减少症的风险,减少了免疫抑制治疗的同时,降低了移植物排斥反应的风险。对中性粒细胞减少症采用替代治疗方法,可能使用粒细胞集落刺激因子,可能会降低移植物排斥反应的风险。一个分辨率更高的图表摘要版本可在补充资料中查看。